Association study of dimethylarginine dimethylaminohydrolase 2 gene polymorphisms and coronary heart disease

Molecular Medicine Reports

Volumn 6, Issue 5, 2012, Pages 1103-1106

  Xu, Ai Guo ^a   Xu, Rong Mei ^b   Lu, Chang Qing ^c   Li, Dan Dan ^a   Xu, Qin Fu ^a   Guo, Jing ^a   Fu, Xin ^a   Zhao, Wei ^a   Yao, Meng Ying ^a  

^a ZHENGZHOU UNIVERSITY   (China)

^b HENAN POLYTECHNIC UNIVERSITY   (China)

^c HENAN UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

Coronary heart disease; Dimethylarginine dimethylaminohydrolase; Polymorphism

Indexed keywords

DIMETHYLARGININASE; DIMETHYLARGININE DIMETHYLAMINOHYDROLASE 2; GLUCOSE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; AGED; ALCOHOL CONSUMPTION; ALLELE; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; GENE FREQUENCY; GENE LOCUS; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SMOKING; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; AGED; AGED, 80 AND OVER; ALLELES; AMIDOHYDROLASES; BLOOD GLUCOSE; BLOOD PRESSURE; CORONARY DISEASE; FEMALE; GENE FREQUENCY; GENETIC LOCI; GENOTYPE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; RISK FACTORS; TRIGLYCERIDES;

EID: 84866443093     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2012.1038     Document Type: Article

References (19)

1. Gaziano TA, Bitton A, Anand S, Abrahams-Gessel S and Murphy A: Growing epidemic of coronary heart disease in low-and middle-income countries. Curr Probl Cardiol 35: 72-115, 2010.
2. Tearney GJ, Regar E, Akasaka T, et al: Consensus standards for acquisition, measurement, and reporting of intravascular optical coherence tomography studies: a report from the International Working Group for Intravascular Optical Coherence Tomography Standardization and Validation. J Am Coll Cardiol 59: 1058-1072, 2012.
3. Kolovou G and Giannakopoulou V: Endothelial nitric oxide synthase gene variants and coronary heart disease. Angiology 63: 84-85, 2012.
4. Chen X, Niroomand F, Liu Z, Zankl A, Katus HA, Jahn L and Tiefenbacher CP: Expression of nitric oxide related enzymes in coronary heart disease. Basic Res Cardiol 101: 346-353, 2006. (Pubitemid 43923391)
5. Jia CQ, Ning Y, Liu TT and Liu ZL: Association between G894T mutation in endothelial nitric oxide synthase gene and premature coronary heart disease. Zhonghua Liu Xing Bing Xue Za Zhi 26: 51-53, 2005 (In Chinese).
6. Celik M, Iyisoy A, Celik T, Yilmaz MI, Yuksel UC and Yaman H: The relationship between L-arginine/ADMA ratio and coronary collateral development in patients with low glomerular filtration rate. Cardiol J 19: 29-35, 2012.
7. Palm F, Onozato ML, Luo Z and Wilcox CS: Dimethylarginine dimethylaminohydrolase (DDAH): expression, regulation, and function in the cardiovascular and renal systems. Am J Physiol Heart Circ Physiol 293: H3227-H3245, 2007. (Pubitemid 350230862)
8. Gad MZ, Hassanein SI, Abdel-Maksoud SM, et al: Assessment of serum levels of asymmetric dimethylarginine, symmetric dimethylarginine and L-arginine in coronary artery disease. Biomarkers, 15: 746-752, 2010.
9. Abhary S, Burdon KP, Kuot A, Javadiyan S, Whiting MJ, Kasmeridis N, Petrovsky N and Craig JE: Sequence variation in DDAH1 and DDAH2 genes is strongly and additively associated with serum ADMA concentrations in individuals with type 2 diabetes. PLoS One 5: e9462, 2010.
10. Maas R, Erdmann J, Lüneburg N, et al: Polymorphisms in the promoter region of the dimethylarginine dimethylaminohydrolase 2 gene are associated with prevalence of hypertension. Pharmacol Res 60: 488-493, 2009.
11. Wang YZ, Xiao JH, Liu LG, Ye CY, Shen HY, Xu TM and Zhu KZ: Simultaneous detection of hepatitis B virus genotypes and mutations associated with resistance to lamivudine, adefovir, and telbivudine by the polymerase chain reactionligase detection reaction. Braz J Infect Dis 15: 560-566, 2011.
12. Alasbahi RH and Melzig MF: Forskolin and derivatives as tools for studying the role of cAMP. Pharmazie 67: 5-13, 2012.
13. Houston M: The role of magnesium in hypertension and cardiovascular disease. J Clin Hypertens (Greenwich) 13: 843-847, 2011.
14. Anthony S, Leiper J and Vallance P: Endogenous production of nitric oxide synthase inhibitors. Vasc Med (Suppl 1) 10: S3-S9, 2005. (Pubitemid 43137262)
15. Maas R: Pharmacotherapies and their influence on asymmetric dimethylargine (ADMA). Vasc Med (Suppl 1) 10: S49-S57, 2005.
16. Tatematsu S, Wakino S, Kanda T, et al: Role of nitric oxide-producing and -degrading pathways in coronary endothelial dysfunction in chronic kidney disease. J Am Soc Nephrol 18: 741-749, 2007. (Pubitemid 46434491)
17. Leiper J, Nandi M, Torondel B, et al: Disruption of methylarginine metabolism impairs vascular homeostasis. Nat Med 13: 198-203, 2007.
18. Zand Parsa AF, Ziai H and Haghighi L: The impact of cardiovascular risk factors on the site and extent of coronary artery disease. Cardiovasc J Afr 23: 197-199, 2012.
19. Jones LC, Tran CT, Leiper JM, Hingorani AD and Vallance P: Common genetic variation in a basal promoter element alters DDAH2 expression in endothelial cells. Biochem Biophys Res Commun 310: 836-843, 2003. (Pubitemid 37188698)